SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. ...

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

French independent pharma major Servier is ramping up its industrial development with the inauguration of a new production unit for the active ingredient of one of its venous medicines. Venous ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...

Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net ...

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...